The reduction in price target from $18 to $7 by a reputable analyst firm like Canaccord Genuity could lead to a negative short-term impact on BioXcel Therapeutics' stock price. This significant decrease suggests a reassessment of the company's future growth prospects or valuation, which could shake investor confidence and result in a downward pressure on the stock price.